CHRISTINE CHILDS: Open Payments
NPI 1952339236 · WINSTON SALEM, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$961 in 48 payments from 12 companies in 2025. Trend: 2023 $1,148 · 2024 $1,298 · 2025 $961
Food & beverage: $961
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 11 | $208 |
| Neurocrine BioSciences, Inc. | 5 | $123 |
| ABBVIE INC. | 6 | $122 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| Janssen Pharmaceuticals, Inc | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $69 |
| Lundbeck LLC | 3 | $59 |
| Neos Therapeutics, LP | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $54 |
| Alkermes, Inc. | 3 | $42 |
Products named: REXULTI, INGREZZA, VRAYLAR, COBENFY, SPRAVATO, TRINTELLIX, Adzenys XR-ODT, CAPLYTA.
Industry payments across NC — which companies pay providers there.
